Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Capital Employed (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Return on Capital Employed for 5 consecutive years, with 0.91% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 50.0% to 0.91% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.91%, a 50.0% increase, with the full-year FY2024 number at 1.05%, down 42.0% from a year prior.
  • Return on Capital Employed was 0.91% for Q3 2025 at Lyra Therapeutics, up from 0.96% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.49% in Q3 2022 to a low of 1.64% in Q1 2025.
  • A 5-year average of 0.95% and a median of 0.81% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: surged 93bps in 2023, then plummeted -104bps in 2025.
  • Lyra Therapeutics' Return on Capital Employed stood at 1.01% in 2021, then soared by 45bps to 0.56% in 2022, then fell by -7bps to 0.6% in 2023, then tumbled by -168bps to 1.61% in 2024, then soared by 43bps to 0.91% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Return on Capital Employed are 0.91% (Q3 2025), 0.96% (Q2 2025), and 1.64% (Q1 2025).